Member Info for Wildforce

Hi Vas .. looks like scib3 is targeting colorectal cancer .. but if Moderna has done its due diligence on immatics .. they will be aware of scancell for sure ..

Take care ..

Just thinking about other scibs .. so I looked up Scib 3 … and this came up …?

https://synapse.patsnap.com/drug/5451bd3046934099a95c8633a3e7a8cc?

Not sure if I’d seen that before ? Knew they had a collab with immatics but wasn’t sure it was still live ??

Take care all ..

Morning all . Thanks for all the comments on the webinar .. couldn’t watch it due to family commitments!

Vanvan .. we know there is already a scib2 .. and in a recent presentation a scib3 and scib4 were noted ? I’m guessing these will be upgraded with avidimab too ??

One thing we do know now is that an insider at Merck has now come across scancell !?

Take care all ..

I think Lisa is going to learn a bit about off the shelf vaccines today ?

Take care all ..

Here’s a bit of info about Lisa Butterfield one of the other panelist’s (Merck) ..

https://www.partnology.com/biotech-leader-spotlight-lisa-h-butterfield-phd/

TF .. exciting indeed .. take care ..

Ah .. found the panel participants..

“ Immunotherapies bring the promise of a cancer -free future – and we’re excited to share our perspectives with the community in a Lumanity event next week.

Scancell CEO Phil L'Huillier will take part in a webinar with other leading biotech/healthcare executives Lisa Butterfield, Michael Kalos, plus Mai-Britt Zocca, Alan Rigby and Marina Udier Blagovic on “Have Cancer Vaccines Come of Age (or Do They Remain the Unruly Adolescent)?”

I don’t think there will be much ‘new’ for those who follow scancell but it will be interesting I’m sure ..

Take care ..

Is this it Vanvan ? Does mention a panel but can’t see any details ? Did I miss a previous link ?

https://lumanity.com/events/have-cancer-vaccines-come-of-age-or-do-they-remain-the-unruly-adolescent/

Some great subject headings being discussed !!

Take care ..

Thanks for confirming Berm.. plenty going on across scancells pipeline ! More chunky black trades today .. just get a sense there is something just around the corner. Something is afoot !?

Take care ..

That value is astonishing .. phase 2 company ..

Thanks Marcus,

Take care …

Specifically SC134 ?

Looks to me to be Glymab related Torquay ?

https://scancell.co.uk/wp-content/uploads/2024/10/glymab_worldadclondon_final_ms_mnv.pdf

Take care ..

From trinity delta report last year..

“It was predicted that iSCIB1+ would stimulate T-cells in the following HLA types: A2, A3, A31, A33, B35 and B44; a broader range of HLA types than SCIB1, hence expanding the target population. There was also an aspiration that by increasing the number of epitopes from gp100 and TRP-2, this could potentially lead to responses in all melanoma patients, given that both are expressed by all pigment producing melanomas. Whilst the latter is generally quite a rare outcome, iSCIB1+ was found to work in the predicted HLA types (as described below) which represent most, about 80%, of melanoma patients, achieving the goal of broadening the target patient population.”

The original Scib1 I believe only had targets for HLA A2 .. so it’s easy to see how much broader the targeting of iScib1+ is ..

Take care all ..

Thanks Vas .. interesting comments .. we await the next chapter then !

Take care ..

“A biotechnology company is considered a "Phase 3 biotech" when its lead drug candidate has successfully passed Phase 2 trials and has initiated or received authorization to begin large-scale, pivotal Phase 3 clinical trials. ”

This is what I was basing my comments on when looking up definition of a phase 3 biotech.

Can understand your point of view though.

Take care ..

Did your opinion of the valuation of scancell change when it successfully achieved completion of the phase 2 with flying colours and is now a phase 3 company ? Because the markets valuation doesn’t seem to have changed ? Can this really be just down to it being on AIM .. A huge inflection point … gone unnoticed as yet !?

Take care ..

Only my opinions as ever ..

Take care all ..

The value gap is crazy isn’t it !! And on top of that Iscib1+ phase 3 will be a registrational trial .. should the benefits be clear and obvious early on in the trial then the wait for commercialisation might not be as long as the usual phase 3 trial …. Could be as short as 12 - 18 months !! Then we are talking those numbers +++

What a story scancell is …

Take care ..

Morning empty .. have you asked google ‘the average value of a phase 3 biotech company’ ?

I don’t want to cut and paste the response just in case I get accused of ramping. Lol .. it’s an easy thing anyone can do.

Take care ..

Hi Berm, that’s quite a number now and is it a sign of Lindy’s work now being understood and accepted by the wider scientific community?

Still can’t believe the market valuation of a phase 3 biotech with such solid phase one and phase two results!

Take care !

More delayed large share ‘transfers’ today ! This has been happening since the Ind for phase 3 iscib1+ was approved ! How long will it go on at this level ??

Take care all ..